Genmab
Genmab is a drug therapy company focused on differentiated antibody products in oncology. The company has developed industry-leading antibody discovery technologies which have led to a strong pipeline of potential best-in-class and first-in-class therapies. Through partnerships Genmab has successfully developed several products, including treatments for multiple myeloma, cervical cancer, multiple sclerosis and thyroid eye disease.
Website besuchen- Unternehmenswert
- US$10.8 bn
- Region
- Denmark
- Thema
- Health
- Unterthema
- Pharmaceutical therapies
Impact-Bewertung
Genmab’s therapies are typically used to treat diseases with very poor outcomes where survival rates are measured in months. Their largest drug has shown significant improvements in progression-free survival and remission rates 6x better than the existing treatments. Clinical studies of pipeline drugs also show promising early data.
Fundamentale Qualität
Genmab’s antibody platform technology is industry-leading. To date it has operated under a partnership model which has allowed it to develop a strong pipeline while generating strong margins and building up a net cash balance sheet. The next stage of growth will see Genmab take a greater share of the economics by participating in the commercialisation stage.
UN-Nachhaltigkeitsziele
Genmab’s therapies support SDG 3 in the context of reducing mortality from non-communicable diseases through treatment.
Mehr erfahrenRisiko negativer Auswirkungen
- Side-effects from pharmaceuticals
- Product pricing restricts access for poor communities
- Plastic waste from packaging
- Animal testing of pharmaceuticals
Verwandte Einblicke Verwandte Inhalte
Sustainable
The next constraint on AI is not just energy, it's also water
Von Ty Lee
10. März 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
Von WHEB Investment Team
17. Feb. 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
Von WHEB Investment Team
19. Jan. 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
Von Seb Beloe
19. Jan. 2026 | 5 min read